iiinova — where your digital self keeps evolving

Replies

ME/CFS Science @mecfsscience.org · 04/08/2025

1) Japanese researchers are recruiting ME/CFS patients for a new randomised trial of Rituximab, a monoclonal antibody that targets the CD20 protein found on B-cells. This is a bit surprising because the Norwegian phase-3 trial of Rituximab had negative results for ME/CFS.

43914

Rob L @robll.bsky.social · 04/08/2025

I think you're going to get varying results because ME/CFS as an inclusion criteria is too wide. I suspect when research is finally done properly, ME we will be re-categorised as several different conditions/diseases.

1122

Firstname Lastname #FuckTrump @notunpackedyet.bsky.social · 04/08/2025

Something something, different B Cells: www.healthrising.org/blog/2025/07... I don't have the health or time to keep up.

healthrising.org

Has the Right B-cell Depleting Drug Been Found for ME/CFS? Daratumumab Shines in Pilot Study - Health Rising

A B-cell depleter called daratumumab does well in an early trial in ME/CFS. A larger trial is underway.

010

ME/CFS Science @mecfsscience.org · 04/08/2025

2) The Japanese group seems to be aware of that. In a press release they say their trial will get a better view of clinical responses by using a different outcome measure and "by having daily symptoms recorded with an app stored on a smartphone." www.ncnp.go.jp/topic...

1100

FionaMECFS @fioname.bsky.social · 04/08/2025

I heard that Norway's results may have been affected because they couldn't afford the right doses of ritux. I have no idea if that's true, though (she hastens to add).

130